logo

For the Inventor, By the Inventor

Boston, MA, United States of America

Paolo Fiorina

This inventor holds 10 USPTO granted patents and 18 published patent applications and 1 EPO patent. Top assignees: Children's Medical Center Corporation, Dompé Farmaceutici S.p.a., Enthera S.r.l.. Active years: 2018-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paolo Fiorina. Retrieved from https://idiyas.com/inventor/paolo-fiorina

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 10 

% Patents Active = 100.0

 

Average Co-Inventor Count = 1.8

ph-index = 1


Company Filing History:

goldMedal8 out of 1,074 
 
Children's Medical Center Corporation
 patents
silverMedal2 out of 55 
 
Dompé Farmaceutici S.p.a.
 patents
bronzeMedal2 out of 3 
 
Enthera S.r.l.
 patents
4. 1 out of 55 
 
Ospedale San Raffaele S.r.l.
 patents
where one patent can have more than one assignee

Years Active: 2018-2025

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents
1. 12221485 - TMEM219 antibodies and therapeutic uses thereof (2025-02-11),
2. 12221476 - Antibodies and uses thereof (2025-02-11),
3. 12097172 - Prevention and treatment of diabetic nephropathy (2024-09-24),
4. 11879137 - Treatment of type 1 diabetes and autoimmune diseases or disorders (2024-01-23),
5. 11642378 - PD-L1 expressing hematopoietic stem cells and uses (2023-05-09),
6. 11452781 - Method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the ATP/P2X7R axis) (2022-09-27),
7. 11291641 - Prevention and treatment of diabetic nephropathy (2022-04-05),
8. 10751373 - PD-L1 expressing hematopoietic stem cells and uses (2020-08-25),
9. 10517899 - PD-L1 expressing hematopoietic stem cells and uses (2019-12-31),
10. 10071167 - Method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the ATP/P2X7R axis) (2018-09-11),

Title: Paolo Fiorina: Innovator in Antibody Research

Introduction

Paolo Fiorina is a prominent inventor based in Boston, MA, known for his significant contributions to the field of antibody research. With a total of 10 patents to his name, Fiorina has made remarkable strides in understanding and utilizing antibodies for therapeutic purposes.

Latest Patents

Fiorina's latest patents include groundbreaking inventions related to antibodies and their uses. One notable patent focuses on an antibody or antigen binding fragment that specifically binds to IGFBP3 without displacing the binding of IGF-I to IGFBP3. This invention is crucial as it inhibits or reduces the binding of IGFBP3 to the TMEM219 receptor. Another significant patent involves TMEM219 antibodies, which are designed to bind specifically to the IGFBP3 receptor, TMEM219. This patent also covers methods for their production, pharmaceutical compositions containing these antibodies, and their therapeutic uses.

Career Highlights

Throughout his career, Fiorina has worked with esteemed organizations such as Children's Medical Center Corporation and Enthera S.r.l. His work in these institutions has allowed him to advance his research and contribute to the development of innovative therapeutic solutions.

Collaborations

Fiorina has collaborated with notable colleagues, including Andrea Vergani and Francesca D'Addio. These partnerships have fostered a collaborative environment that enhances the research and development of new antibody therapies.

Conclusion

Paolo Fiorina's contributions to antibody research have positioned him as a leading inventor in the field. His innovative patents and collaborations continue to pave the way for advancements in therapeutic applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…